| Literature DB >> 28364028 |
Emilie Bernatchez1, Matthew J Gold2, Anick Langlois1, Pascale Blais-Lecours1, Magali Boucher1, Caroline Duchaine1, David Marsolais1, Kelly M McNagny2, Marie-Renée Blanchet3.
Abstract
Despite improved awareness of work-related diseases and preventive measures, many workers are still at high risk of developing occupational hypersensitivity airway diseases. This stems from a lack of knowledge of bioaerosol composition and their potential effects on human health. Recently, archaea species were identified in bioaerosols, raising the possibility that they play a major role in exposure-related pathology. Specifically, Methanosphaera stadtmanae (MSS) and Methanobrevibacter smithii (MBS) are found in high concentrations in agricultural environments and respiratory exposure to crude extract demonstrates immunomodulatory activity in mice. Nevertheless, our knowledge of the specific impact of methanogens exposure on airway immunity and their potential to induce airway hypersensitivity responses in workers remains scant. Analysis of the lung mucosal response to methanogen crude extracts in mice demonstrated that MSS and MBS predominantly induced TH17 airway inflammation, typical of a type IV hypersensitivity response. Furthermore, the response to MSS was associated with antigen-specific IgG1 and IgG2a production. However, despite the presence of eosinophils after MSS exposure, only a weak TH2 response and no airway hyperresponsiveness were observed. Finally, using eosinophil and mast cell-deficient mice, we confirmed that these cells are dispensable for the TH17 response to MSS, although eosinophils likely contribute to the exacerbation of inflammatory processes induced by MSS crude extract exposure. We conclude that, as MSS induces a clear type IV hypersensitivity lung response, it has the potential to be harmful to workers frequently exposed to this methanogen, and that preventive measures should be taken to avoid chronic hypersensitivity disease development in workers.Entities:
Keywords: Eosinophils; IL‐17; hypersensitivity response; lung; methanogens
Mesh:
Substances:
Year: 2017 PMID: 28364028 PMCID: PMC5392504 DOI: 10.14814/phy2.13163
Source DB: PubMed Journal: Physiol Rep ISSN: 2051-817X
Figure 1MSS induces a mixed T2/T17 immune lung response. (A) Timeline of the model of exposure to methanogens. Full line represents intranasal instillation of either PBS, MSS or MBS crude extract while dashed line represents day of euthanasia. (B) Flow cytometry gating strategy for the polarity of the effector lung response after ex‐vivo stimulation of lung leukocytes isolated from methanogen‐exposed mice. CD4+ T cells were gated from total lung cells and cytokine‐positive cells were analyzed using Fluorescence Minus One (FMO) controls. (C) Severity of the inflammatory lung response after 3 μg MSS exposure was measured using total broncho‐alveolar lavage (BAL) count and differential count. (D) Polarity of the effector response evaluated as number and the % of CD4+ cells expressing IFNg, IL‐13 or IL‐17A. (E) Il13 and Il17a expression measured by qRT‐PCR on lung tissue of mice exposed to MSS compared with PBS. (F) MSS‐specific IgG1 and IgG2a and total IgE production was measured from serum using ELISA. Results are representative of at least three separate experiments; n = 3–6 mice/group. * = P ˂ 0.05.
Figure 2MSS mainly induces a T17 polarized immune response. (A) Severity of the inflammatory response following exposure to 3 μg versus 100 μg of MSS was quantified using total broncho‐alveolar lavage (BAL) count and differential count. Results are representative of at least three separate experiments; n = 3–6 mice/group. * = P ˂ 0.05. (B) Polarity of the effector response evaluated as number and the % of CD4+ cells expressing IFNg, IL‐13 or IL‐17A. (C) MSS‐specific IgG1 and IgG2a production was measured from serum using ELISA. Results were pooled from two experiments; n = 6–10 mice/group. † = P ˂ 0.05 with multi‐comparison test. Using the Flexivent Apparatus, (D) airway resistance (Rrs) was evaluated in mice exposed to 3 μg or 100 μg MSS. Results were pooled from two experiments; n = 6–12 mice/group. * = P ˂ 0.05.
Figure 3MBS induces a weak T17 immune lung response. (A) Severity of the inflammatory lung response after 6.25 μg MBS exposure was measured using total broncho‐alveolar lavage (BAL) count and differential count. (B) Polarity of the effector response evaluated as number and the % of CD4+ cells expressing IFNg, IL‐13 or IL‐17A. (C) MBS‐specific IgG1 and IgG2a production was measured from serum using ELISA. Results are representative of at least three separate experiments; n = 3–6 mice/group. * = P ˂ 0.05.
Figure 4IL‐17A blockade leads to reduced total inflammation and eosinophil influx in the airways. (A) Expression of Ccl11, Ccl24, and Il33 measured by qRT‐PCR. (B) The % of ILC2s (Lineage− CD45+Sca1+ CD90.2+ CD25+ ST2+) in lung of mice exposed to MSS compared with PBS. (C) The severity of the inflammatory lung response in mice that received isotype or anti‐IL‐17A 1 h before each exposure to 3 μg MSS was verified using broncho‐alveolar lavage (BAL) count. Results were pooled from two experiments; n = 6–12 mice/group. * = P ˂ 0.05.
Figure 5Eosinophils and mast cells are not essential for the development of MSS‐induced airway inflammation. (A) The inflammatory lung response was verified in ΔdblGATA mice after exposure to 3 μg MSS using broncho‐alveolar lavage (BAL) count and differentials. (B) Polarity of the effector response evaluated as number and the % of CD4+ cells expressing IFNg, IL‐13 or IL‐17A. (C) Using BAL count, the inflammatory lung response was verified in Cpa3‐cre mice after exposure to 3 μg MSS. Results were pooled from two experiments; n = 6–12 mice/group. * = P ˂ 0.05.